Novo Nordisk Stock Tumbles Monday to Its Lowest Point in Nearly 5 Years. Here's Why

Core Insights - Novo Nordisk's stock has dropped over 15% following disappointing clinical trial results for its weight-loss drug CagriSema, which showed an average weight loss of 23% after 84 weeks, lower than the 25.5% achieved by Eli Lilly's tirzepatide [1][1][1] - The decline in Novo Nordisk's shares marks a significant downturn, with the stock losing more than half its value over the past 12 months, reaching its lowest point in nearly five years [1][1][1] - In contrast, Eli Lilly's stock has seen a 19% increase over the past year, with the company projecting continued sales growth [1][1][1] Company Performance - Novo Nordisk's CagriSema trial results have raised concerns about its competitive position in the weight-loss drug market, particularly against Eli Lilly's products [1][1] - Eli Lilly has recently introduced a new multi-dose version of its injectable drug Zepbound, further enhancing its market presence [1][1] - The divergence in stock performance between Novo Nordisk and Eli Lilly highlights the shifting dynamics in the weight-loss drug sector, with Eli Lilly's sales accelerating while Novo Nordisk's have slowed [1][1][1]